Drug in Focus: Regorafenib (Stivarga)


The majority of patients with metastatic colon or rectal cancer (mCRC) cannot be cured, although a sub-set with liver and/or lung-isolated metastatic disease, local recurrence, or limited intra-abdominal disease are potentially curable with surgery. For other patients with mCRC, treatment is palliative and generally consists of systemic chemotherapy. Medical Grapevine recently sat down with Dr Tan Yew […]

Dysport (abobotulinumtoxinA)


Produced by the bacterium Clostridium botulinum, botulinum toxin is a neurotoxin available in seven distinct serotypes (A, B, C, D, E, F and G) – serotype A being the most potent. All serotypes interfere with neural transmission by blocking the release of acetylcholine, the principal neurotransmitter at the neuromuscular junction, thereby causing muscle paralysis. Recovery […]

EYLEA (aflibercept) : In Focus


EYLEA (aflibercept) is an anti-angiogenic therapy approved for wet age-related macular degeneration (AMD) – a chronic eye disease that causes vision loss in the centre of the field of vision due to abnormal blood vessels that leak fluid or blood into the region of the macula. With proven efficacy in a proactive approach to wet […]

Drug in Focus: Abiraterone Acetate (Zytiga)


New drug for the treatment of advanced prostate cancer When prostate cancer spreads to another location in the body, it is considered to have metastasised, and surgery to remove the prostate and pelvic lymph nodes cannot eliminate the cancer. As a result, most men with metastatic prostate cancer (PCa) receive hormonal therapy which is also […]

Drug in Focus: Amlodipine and Valsartan


Drug in Focus: Amlodipine and Valsartan In the event that one hypertension drug is not enough, a combination pill of amlodipine (a calcium channel blocker) and valsartan (an angiotensin receptor blocker) can be prescribed to qualified patients. Recently, Medical Grapevine asked Dr Pipin Kojodjojo regarding the CCB + ARB combination pill against hypertension, especially on […]

Drug in Focus: Linagliptin


Drug in Focus: Linagliptin What is linagliptin and how does it compare to other Type 2 diabetes medications? Dr Wu: Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor which prevents the degradation of the incretin hormones to improve plasma glucose levels. When compared with other anti-hyperglycaemic agents, DPP-4 inhibitors have been shown to have similar efficacy […]

Drug in Focus: Dabigatran Etexilate

Drug in Focus: Dabigatran Etexilate Dr Low Lip Ping shares with Medical Grapevine, the indication, dosage management and the benefits of dabigatran etexilate (Pradaxa®)– novel oral anticoagulant for stroke risk reduction in patients with non-valvular atrial fibrillation (AF). How is managing anti-coagulation from dabigatran different from that caused by heparin or warfarin? Does dabigatran pose […]

Drug in Focus: ELONVA® (corifollitropin alfa injection)

Drug in Focus: ELONVA® (corifollitropin alfa injection) Launched in May by MSD in Singapore, ELONVA® (corifollitropin alfa injection) is a new treatment for fertility approved for Controlled Ovarian Stimulation (COS) in combination with a GnRH antagonist for the development of multiple follicles in women participating in an Assisted Reproductive Technology (ART) program. Recently, Medical Grapevine […]

Drug in Focus: Tadalafil

Image for illustration purposes

Drug in Focus: Tadalafil This month’s drug in focus – tadalafil –is known popularly as “The Weekend Drug” because of its 36 hour effectiveness. Compared to other two PE5 inhibitors in the market, it is the only one of the three in the present market that is also offered as a once-daily medication. The following are questions and requested clarifications […]

Drug in Focus: Denosumab


Drug in Focus: Denosumab Answers to questions kindly provided by: Associate Professor Lau Tang Ching Head & Senior Consultant, Division of Rheumatology, NUH  1. What are the indications of denosumab? Are there specific criteria where use of the drug should be considered? Denosumab is a potent anti-resorptive medication that prevents bone loss and therefore is […]

Copyright © 2013 All rights reserved. Content and images are meant for practicing medical doctors, allied health care professionals and other establishments in the medical industry. Reproduction or redistribution of any content and images, is prohibited without the prior written consent of Ezyhealth Media Pte Ltd.